The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
Terminated
University of Chicago
Phase 2
2013-08-01
The purpose of this study is to assess if estrogen replacement normalizes urinary calcium
excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for
differences in response to estrogen replacement in women with familial hypercalciuria
compared to nonfamilial hypercalciuria.
Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy
Withdrawn
Medical College of Wisconsin
N/A
2014-06-01
This will be a 4-way comparison to prospectively evaluate the efficacy and patient
tolerability of four commercially available bowel preparations among patients undergoing
colonoscopy for screening and surveillance in a single tertiary academic medical center.
Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening
Withdrawn
Mercy Medical Center, Des Moines, Iowa
N/A
2016-03-01
The purpose of this study is to investigate Suprep bowel preparation, with and without the
anti-gas medication simethicone, in terms of efficacy and patient tolerability in the
preparation of patients undergoing routine colonoscopy for colorectal cancer screening.
Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening
Withdrawn
MercyOne Des Moines Medical Center
N/A
2016-03-01
The purpose of this study is to investigate Suprep bowel preparation, with and without the
anti-gas medication simethicone, in terms of efficacy and patient tolerability in the
preparation of patients undergoing routine colonoscopy for colorectal cancer screening.
Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
Unknown status
Alphacait, LLC
Phase 2
2017-01-01
This is a single-center, open-label, single-arm, non-randomized study designed to evaluate
PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR)
and biomarkers of cancer therapy based on Alphacait screening system in subjects with
advanced malignant tumor.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
